Regulatory toxicology and pharmacology : RTP
April 1, 2011
Jan Van Amsterdam, Antoon Opperhuizen, Wim van den Brink
208 citations
Magic mushroom use in the Netherlands declined from 6.3% last-year prevalence in 2000 to 2.9% in 2005, and further after possession and use became illegal in December 2008. A review by the Coordination point Assessment and Monitoring new drugs concluded that the physical and psychological dependence potential of magic mushrooms is low, acute toxicity moderate, chronic toxicity low, and public health and criminal aspects negligible. Combined use with alcohol and the quality of the setting deserve attention. Overall, magic mushroom use is relatively safe with few and mild adverse effects, though the low but unpredictable provocation of panic attacks and flash-backs remain a concern.
Expert Opinion on Drug Safety
February 26, 2022
Jan Van Amsterdam, Wim van den Brink
74 citations
Psilocybin, when combined with psychotherapy or psychotherapeutic support, shows promise as a treatment for various mental disorders, including treatment-resistant conditions. However, larger double-blind randomized controlled trials with objective long-term outcomes are needed to confirm these findings before standard clinical use can be considered.
Frontiers in psychiatry
January 1, 2022
Joost J Breeksema, Alistair Niemeijer, Bouwe Kuin et al.
41 citations
Patients with treatment-resistant depression undergoing oral esketamine treatment often find the experience overwhelming and struggle with whether to let go or maintain control. Their ability to let go is influenced by preparation, emotional support, and the treatment setting. Better preparation, an optimized environment, and psychological support during sessions may improve patients' experiences and outcomes. The study provides recommendations for improving quality of care, including training for nurses and support staff.
Psychopharmacology
July 1, 2023
Joost J Breeksema, Alistair Niemeijer, Bouwe Kuin et al.
26 citations
The effects of oral esketamine for treatment-resistant depression are highly variable, and psychological distress is common. Patients report perceptual changes, detachment from body and emotions, stillness, mystical-type experiences, and fear. After sessions, many feel hungover and fatigued, while depressive mood is neutralized. Some effects, such as increased openness and detachment, may hold psychotherapeutic potential, but the frequent distress calls for additional patient support throughout treatment.
Drugs Education Prevention and Policy
September 10, 2020
Jan Van Amsterdam, Johannes G. Ramaekers, Ton Nabben et al.
4 citations
Ecstasy (MDMA) is a popular recreational drug with low abuse and dependence liability compared to several other illicit drugs and alcohol, and there is little evidence of long-term harm. A potential health risk is acute hyperthermia, which occurs at an unknown incidence rate and is more prevalent when ecstasy is consumed with heavy exercise at high ambient temperatures or with other substances including alcohol. However, illegal production and trade in the Netherlands have developed into a serious public order and ecological problem, with organized crime related to production and trafficking growing. This review provides a science-based summary to assist debate on future Dutch ecstasy policy to reduce organized crime while maintaining harm reduction.